Biodexa Pharmaceuticals annual ebitda
2015
2016
2017
2018
2022
2023
2024
2025
Biodexa Pharmaceuticals EBITDA Growth & History (BDRX)
Biodexa Pharmaceuticals's calculated EBITDA was −£6.1M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£6.1M | −£511,000 | — |
| 2024 | 2024-12-31 | −£5.6M | £1.6M | — |
| 2023 | 2023-12-31 | −£7.2M | £931,000 | — |
| 2022 | 2022-12-31 | −£8.1M | — | — |
| 2018 | 2018-12-31 | −£11.7M | £1.5M | — |
| 2017 | 2017-12-31 | −£13.2M | −£3.6M | — |
| 2016 | 2016-12-31 | −£9.6M | £3.3M | — |
| 2015 | 2015-12-31 | −£12.9M | — | — |
Biodexa Pharmaceuticals ebitda trends
Between the periods ended 2015-12-31 and 2025-12-31, Biodexa Pharmaceuticals's ebitda increased from −£12.9M to −£6.1M, a change of £6.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...